The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Homenko Ju.G.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Kataeva G.V.

Institut mozga cheloveka im. N.P. Bekhterevoĭ RAN, Sankt-Peterburg

Bogdan A.A.

N. Bechtereva Institute of the Human Brain, Russian Acsdemy of Sciences, St. Petersburg

Chernysheva E.M.

N. Bekhtereva Institute of the Human Brain, Russian Academy of Sciences, St.-Petersburg, Russia

Susin D.S.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Cerebral metabolism in patients with cognitive disorders: a combined MRS and PET study

Authors:

Homenko Ju.G., Kataeva G.V., Bogdan A.A., Chernysheva E.M., Susin D.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(1): 51‑58

DOI: 10.17116/jnevro201911901151

Read: 2430 times

Download PDF (RU)
Contact the author
Table of contents

CEREBRAL METABOLISM IN PATIENTS WITH COGNITIVE DISORDERS: A COMBINED MRS AND PET STUDY
CEREBRAL METABOLISM IN PATIENTS WITH COGNITIVE DISORDERS: A COMBINED MRS AND PET STUDY

To cite this article:

Homenko JuG, Kataeva GV, Bogdan AA, Chernysheva EM, Susin DS. Cerebral metabolism in patients with cognitive disorders: a combined MRS and PET study. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(1):51‑58. (In Russ.)
https://doi.org/10.17116/jnevro201911901151

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Mediastinal staging in planning the mana­gement of patients with non-small cell lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(2):57-63
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Abstract:

Objective. Magnetic resonance spectroscopy (MRS) allows studying the content of many metabolites in neural tissue in vivo. There are numerous studies devoted to the MRS data analysis in Alzheimer’s disease (AD), but their results are contradictory. Thus, it is rational to compare the data obtained with MRS and positron emission tomography (PET) with fluorodeoxyglucose (FDG), which allows evaluating the brain functional state. In this paper, the authors compared MRS data in AD and mild cognitive impairment (MCI) with the cerebral glucose metabolism changes according to FDG PET. Material and methods. Multivoxel proton MRS of the supraventricular area was performed in patients with AD (n=16) and MCI (n=14). The following metabolites ratios were evaluated: NAA/Cr, Cho/Cr, NAA/Cho (NAA — N-acetylaspartate, Cr — creatine, Cho — choline). All patients underwent neurological examination, assessment of cognitive status and PET with FDG. Results. A decrease in NAA/Cr and Cho/Cr ratios in the supraventricular white matter and medial cortex in both hemispheres was observed in AD patients. In the MCI group, NAA/Cr ratio were decreased only in left white matter adjusting to the parietal cortex. Positive correlations of NAA/Cr and Cho/Cr ratios with cognitive status, as well as the cerebral glucose metabolism rate according to the PET data in frontal, parietal, temporal and cingulate cortex were revealed. Conclusions. The decrease in the NAA/Cr ratio in the supraventricular white matter and the medial cortex in AD and the correlation of this index with the results of cognitive tests and cerebral glucose metabolism suggest that it can be of diagnostic significance, reflecting the severity of cognitive impairment. In this case, the NAA/Cr ratio should be evaluated taking into account the changes in concentrations of both metabolites (NAA and Cr) in dementia.

Keywords:

magnetic resonance spectroscopy
Alzheimer’s disease
cognitive impairment
N-acetylaspartate
choline
creatine
positron emission tomography

Authors:

Homenko Ju.G.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Kataeva G.V.

Institut mozga cheloveka im. N.P. Bekhterevoĭ RAN, Sankt-Peterburg

Bogdan A.A.

N. Bechtereva Institute of the Human Brain, Russian Acsdemy of Sciences, St. Petersburg

Chernysheva E.M.

N. Bekhtereva Institute of the Human Brain, Russian Academy of Sciences, St.-Petersburg, Russia

Susin D.S.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Close metadata

References:

  1. Tabert M, Liu X, Doty R, Serby M, Zamora D, Pelton G, Marder K, Albers M, Stern Y, Devanand D. A 10-item smell identification scale related to risk for Alzheimer’s disease. Ann Neurol. 2005;58(1):155-160.
  2. Verdile G, Fuller S, Atwood C, Lawsa S, Gandye S, Martins R. The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught? Pharmacological Research. 2004;50:397-409.
  3. Mathis C, Mason N, Lopresti B, Klunk W. Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med. 2012;42(6):423-432. https://doi.org/10.1053/j.semnuclmed.2012.07.001
  4. Trzepacz P, Yu P, Sun J, Schuh K, Case M, Witte M, Hochstetler H, Hake A. Alzheimer’s Disease Neuroimaging Initiative. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer’s dementia. Neurobiol Aging. 2014;35(1):143-151. https://doi.org/10.1016/j.neurobiolaging.2013.06.018
  5. Magnetic Resonance Neuroimaging. Methods in Molecular Biology. Modo M, Bulte J, eds. Springer. 2011. https://doi.org/10.1007/978-1-61737-992-5_9
  6. Barker PB, Bizzi A, De Stefano N, Gullapalli RP, Lin DM. Clinical MR Spectroscopy: Techniques and Applications. Cambridge University Press; 2009.
  7. Haga KK, Khor YP, Farrall A, Wardlaw JM. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiology of Aging. 2009;30:353-363. https://doi.org/10.1016/j.neurobiolaging.2007.07.005
  8. Magnetic resonance spectroscopy. Tools for Neuroscience Research and Emerging Clinical Applications. Stagg C, Rothman D, eds. Elsevier. 2014.
  9. Semenova NA, Akhadov TA, Petryaykin AV, Sidorin SS, Lukovenkov AV, Varfolomeev SD. Metabolic disorders and interrelations of metabolic processes in human frontoparietal cortex in severe traumatic brain injury. Single voxel 1H magnetic resonance spectroscopy study. Biokhimiya. 2012;77(4):493-500. (In Russ.)
  10. Hetherington HP, Mason GF, Pan JW, Ponder SL, Vaughan JT, Twieg DB, Pohost GM. Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T. Magn Reson Med. 1994;32(5):565-571. https://doi.org/10.1002/mrm.1910320504
  11. Shiino A, Matsuda M, Morikawa S, Inubushi T, Akiguchi I, Handa J. Proton magnetic resonance spectroscopy with dementia. Surg Neurol. 1993;39(2):143-147. https://doi.org/10.1016/0090-3019(93)90093-g
  12. Kantarci K, Petersen RC, Boeve BF. 1H-MR spectroscopy in common dementias. Neurology. 2004;63(8):1393-1398. https://doi.org/10.1212/01.wnl.0000141849.21256.ac
  13. Wang H, Tan L, Wang HF, Liu Y, Yin RH, Wang WY, Chang XL, Jiang T, Yu JT. Magnetic Resonance Spectroscopy in Alzheimer’s Disease: Systematic Review and Meta-Analysis. J Alzheimers Dis. 2015;46(4):1049-1070. https://doi.org/10.3233/JAD-143225
  14. Frederick BB, Satlin A,Yurgelun-Todd DA, Renshaw PF. In vivo proton magnetic resonance spectroscopy of Alzheimer’s disease in the parietal and temporal lobes. Biol Psychiatry. 1997;42(2):147-150. https://doi.org/10.1016/s0006-3223(97)00242-4
  15. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassman H, Frahm J, Bruck W. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol. 1999;20(9):1619-1627.
  16. Jessen F, Block W, Traber F. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology. 2000;55:5:684-688. http://www.ajnr.org/content/20/9/1619
  17. Huang W, Alexander GE, Chang L, et al. Brain metabolite concentration and dementia severity in Alzheimer’s disease: a (1)H MRS study. Neurology. 2001;57(4):626-632. https://doi.org/10.1212/wnl.57.4.626
  18. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med. 1999;41(2):276-284. https://doi.org/10.1002/(sici)1522-2594(199902)41:2<276::aid-mrm10>3.3.co
  19. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry. 2003;160(11):2003-2011. https://doi.org/10.1176/appi.ajp.160.11.2003
  20. Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y. Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol. 2002;59(6):955-962. https://doi.org/10.1001/archneur.59.6.955
  21. Tumati S, Martens S, Aleman A. Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2571-2586. https://doi.org/10.1016/j.neubiorev.2013.08.004
  22. Zhang B, Ferman TJ, Boeve BF, Smith GE, Maroney-Smith M, Spychalla AJ, Knopman DS, Jack CR Jr, Petersen RC, Kantarci K.MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer’s disease. J Neuroimaging. 2015;25(2):269-274. https://doi.org/10.1111/jon.12138
  23. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Clifford RJ. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology. 2008;248(1):210-220. https://doi.org/10.1148/radiol.2481071590
  24. Coutinho AMN, Porto FHG, Zampieri PF, Otaduy MC, Perroco TR, Oliveira MO, Nunes RF1, Pinheiro TL3, Bottino CMC2, Leite CC3, Buchpiguel CA. Analysis of the posterior cingulate cortex with [18F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer’s disease: Correlations and differences between the two methods. Dement Neuropsychol. 2015;9(4):385-393. https://doi.org/10.1590/1980-57642015DN94000385
  25. Medvedev SV, Skvortsova TYu, Krasikova RN. PET in Russia: positron emission tomography in clinic and physiology. SPb. 2008 (In Russ.)
  26. Bogdan AA, Khomenko YuG, Kataeva GV, Trofimova TN. Principles of data grouping in assessment of human brain multivoxel spectroscopic studies. Luchevaya diagnostica I terapiya. 2016;4(7):15-19. (In Russ.)
  27. Charlton RA, McIntyre DJ, Howe FA, Morris RG, Markus HS. The relationship between white matter brain metabolites and cognition in normal aging: The GENIE study. Brain Research. 2007;1164:108-116. https://doi.org/10.1016/j.brainres.2007.06.027
  28. Allman JM, Tetreault NA, Hakeem AY, Manaye KF, Semendeferi K, Erwin JM, Park S, Goubert V, Hof PR. The von Economo neurons in fronto-insular and anterior cingulate cortex. Ann NY Acad Sci. 2011;1225:59-71. https://doi.org/10.1111/j.1749-6632.2011.06011.x
  29. Talairach J, Tournoux P. Co-planar stereotactic atlas of the human brain: 3-dimensional proportional system: an approach to cerebral imaging. Thieme New-York. 1988.
  30. Statistical Parametric Mapping. www.fil.ion.ucl.ac.uk/spm/
  31. WFU PickAtlas. http://www.nitrc.org/projects/wfu_pickatlas/
  32. Yakushev I, Landvogt C, Buchholz HG, Fellgiebel A, Hammers A, Scheurich A, Schmidtmann I, Gerhard A, Schreckenberger M, Bartenstein P. Choice of reference area in studies of Alzheimer’s disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res. 2008;164(2):143-153. https://doi.org/10.1016/j.pscychresns.2007.11.004
  33. Khomenko YuG, Bogdan AA, Kataeva GV, Chernysheva EM. Implementation of magnetic resonance spectroscopy in the examination of patients with cognitive impairment. Vestnik Sankt-Peterburgskogo Universiteta. Seriya 4. Fizika. Khimiya. 2016;3(1):82-89. (In Russ.)
  34. Schuff N, Amend DL, Meyerhoff DJ, Tanabe JL, Norman D, Fein G, Weiner MW. Alzheimer Disease: Quantitative H-1 MR Spectroscopic Imaging of Frontoparietal Brain. Radiology. 1998;207(1):91-102.
  35. Gromova EA, Bogdan AA, Kataeva GV, Kotomin IA, Khomenko YuG, Korotkov AD, Trofimova TN, Rassohin VV, BeliakovNA. Peculiarities of functional structures of the brain in HIV infected patients. Luchevaya diagnostica i terapiya. 2016;1:41-48. (In Russ.)
  36. Weissenborn K, Ahl B, Fischer-Wasels D, Hoff J, Hecker H, Burchert W, Kostler H. Correlations between magnetic resonance spectroscopy alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy. Gut. 2007;56(12):1736-1742. https://doi.org/10.1136/gut.2006.110569
  37. Mielke R, Schopphoff HH, Kugel H, Pietrzyk U, Heindel W, Kessler J, Heiss WD. Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer’s disease. Int J Neurosci. 2001;107(3-4):233-245. https://doi.org/10.3109/00207450109150687
  38. O’Neill J, Eberling JL, Schuff N, Jagust W, Reed B, Soto G, Ezekiel F, Klein G, Weiner MW. Method to correlate 1H MRSI and 18FDG-PET. Magn Reson Med. 2000;43(2):244-50. https://doi.org/10.1002/(sici)1522-2594(200002)43:2<244::aid-mrm11>3.3.co
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.